目次

Contents

1. Executive Summary

2. Pharmaceutical Contract Packaging Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Macro-Economic Indicators

6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8. Recent Development, Policies & Regulatory Landscape

9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10. Pharmaceutical Contract Packaging Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11. Pharmaceutical Contract Packaging Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12. Pharmaceutical Contract Packaging Market : Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
Company Profile
Amcor plc,
Ball corporation,
Nipro Corporation,
Daito Pharmaceutical Co., Ltd.,
Pfizer CentreOne,
West Pharmaceutical Services, Inc.,
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

市場概要
Market Overview
Fatpos Global has released a report titled Oral Antidiabetic Drugs Market - Analysis of Market Size, Share & Trends for 2014 - 2020 and Forecasts to 2031. According to a study by Fatpos Global, is anticipated to reach USD66.30billion by 2030 at CAGR of 5.6% over the period from 2021 to 2030.. According to the report, emphasizes on the detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demands, industry and CAGR in order to provide a comprehensive outlook of the global market

Contents

1. Executive Summary

2. Oral Antidiabetic Drugs Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Macro-Economic Indicators

6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8. Recent Development, Policies & Regulatory Landscape

9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10. Oral Antidiabetic Drugs Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11. Oral Antidiabetic Drugs Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12. Oral Antidiabetic Drugs Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

Company Profile
Sanofi S.A.
Eli Lilly and Company
AstraZeneca plc
Astellas Pharma Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck And Co.
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.